



**ASX Announcement**  
**27 June 2022**

## **OPTISCAN IMAGING ANNOUNCES STRATEGIC DISTRIBUTION PARTNERSHIP FOR CHINA**

### **Highlights:**

- Optiscan announces a new strategic partnership with China based Sinsi Technology Co Ltd. for distribution of its ViewnVivo® (FIVE2) research and pre-clinical device.
- Sinsi Technology Co Ltd. is a trusted and established Chinese distributor within the science and biotechnology sectors.
- This agreement further expands Optiscan's global footprint and signals stable long-term growth.

Optiscan Imaging Limited (ASX: OIL) is pleased to advise an exciting new distributor partnership with Sinsi Technology Co Ltd with a focus on the greater China market, including Hong Kong and Macau. It excludes the greater Shanghai area and Taiwan, where Optiscan already has existing relationships with local distributors. The agreement covers the innovative ViewnVivo® device, focused on the pre-clinical and research sectors.

Optiscan's CEO and Managing Director, Prof. Camile Farah said, "This new agreement further enhances the reach of our innovative technology into an important and significant segment of the global scientific research market. China represents an excellent growth opportunity for Optiscan's ViewnVivo® product across a range of research and pre-clinical application areas. This is very exciting for Optiscan and for the many research institutes across the broader Chinese market, that now have access to our innovative and cutting-edge technology platform. With the appointment of Sinsi Technology as a new China distributor, Optiscan continues to diversify its revenue stream and cash flow geographically, whilst expanding its potential customer base."

Mr Yan Wang, General Manager of Sinsi Technology Co Ltd., said, "After more than 20 years of development, Sinsi has accumulated an extensive customer base in life sciences in Greater China, and is looking forward to assisting Optiscan grow its market share while helping more scientists in China benefit from Optiscan's ViewnVivo® imaging platform. The Optiscan ViewnVivo® system is based on a very distinctive and innovative technology which produces in vivo microscopic imaging of the highest quality, that will undoubtedly increase access to pre-clinical imaging modalities for China based scientists and medical researchers."

This announcement has been authorised for release by the Board of Optiscan and Sinsi Technology Co Ltd.

--ends--

### **For investor queries, please contact:**

Prof Camile Farah  
CEO & Managing Director – Optiscan Imaging Ltd  
E: [cfarah@optiscan.com](mailto:cfarah@optiscan.com)

For more information about our products, visit [www.optiscan.com](http://www.optiscan.com)

### **About Optiscan**

Optiscan Imaging Ltd (ASX:OIL) is a global leader in the development, manufacturing, and commercialisation of confocal endomicroscopic imaging technologies for medical, translational and pre-clinical applications. Our technology enables real-time, non-destructive, 3D, *in-vivo* imaging at the sub-cellular level.

**Phone** (61 3) 9538 3333

**Website** [www.OptiScan.com](http://www.OptiScan.com)

16 Miles St, Mulgrave VIC 3170

We are driven by developing technology and its use to give healthcare providers and researchers the highest quality real-time microscopic imaging tools to enable the early detection and management of disease, improve patient outcomes, and reduce the high cost of curative medicine and associated procedures.

Our patent-protected proprietary technology, using specially miniaturised componentry, has created a pen-sized digital microscope, which can be used on any tissue it contacts to produce high resolution digital pathology images for cancer diagnosis and surgical margin detection in real-time. The aim of our technology development is for earlier diagnosis and subsequent treatment of cancerous tumours with expected associated improved patient outcomes.

### **About Sinsi Technology Co Ltd**

Sinsi Technology has over 20 years of experience representing a range of international organisations in China in the life science and biotechnology sectors. They focus on domestic integration and advancement of global products into the China research and development market space. They also have an established service network across greater China which further enhances their ability to represent Optiscan to the market.

### **Disclaimer**

*All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of OptiScan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as 'anticipate', 'believe', 'could', 'estimate', 'expect', 'future', 'intend', 'may', 'opportunity', 'plan', 'potential', 'project', 'seek', 'will' and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of OptiScan that could cause actual results to differ from the results expressed or anticipated in these statements.*